Somanetics books robust Q2 that beats the Street
Somanetics Corp. (Nasdaq:SMTS), which offers a patient monitoring system that measures changes in the blood oxygen levels, this morning reported a 40% increase in fiscal second-quarter revenues and a 23% increase in net income, both of which trumped the consensus on Wall Street. The firm attributed robust results to a 76% increase in revenue from its corner stone product, Invos System monitor, and a 28% increase in sensor revenue from the year-ago quarter.
Somanetics also reiterated guidance for the full year.
Shares popped up 7%, or $1.45, to $22 in pre-market trading. For detailed price information and recent news stories about Somanetics, click SMTS.
